Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia

Dr. Moshe Talpaz

Oncology | Hematology
Regents Of The University Of Michigan
1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
Accepting New Patients
Offers Telehealth
48 Years of Experience
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Regents Of The University Of Michigan
1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Moshe Talpaz is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Talpaz has been practicing medicine for over 48 years and is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Myelofibrosis, Chronic Myelogenous Leukemia (CML), Myeloproliferative Neoplasms (MPN), and Polycythemia Vera. Dr. Talpaz is currently accepting new patients.

His clinical research consists of co-authoring 151 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in MI
Hospital Affiliations
University Of Michigan Health System
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
McLaren Health
  • HMO
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

REGENTS OF THE UNIVERSITY OF MICHIGAN
1500 E Medical Ctr, Suite 0331, Ann Arbor, MI 48109
Other Locations
REGENTS OF THE UNIVERSITY OF MICHIGAN
1500 E Medical Ctr Dr, Ann Arbor, MI 48109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Study Phase: Phase 3
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Enrollment Status: Completed
Publish Date: July 04, 2025
Intervention Type: Drug
Study Drug: ABL001
Study Phase: Phase 3
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: ABL001, Bosutinib
Study Phase: Phase 3
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: Tagraxofusp
Study Phase: Phase 1/Phase 2
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Drug
Study Drugs: ABL-001, Dasatinib, Nilotinib, Imatinib
Study Phase: Phase 1
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 07, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
Enrollment Status: Terminated
Publish Date: November 15, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: APTO-253
Study Phase: Phase 1
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 08, 2021
Intervention Type: Drug
Study Drugs: INCB053914, I-DAC (Intermediate Dose Cytarabine), Azacitidine, Ruxolitinib
Study Phase: Phase 1/Phase 2
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
Enrollment Status: Terminated
Publish Date: March 05, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 12 Less Clinical Trials

151 Total Publications

Effects of Calreticulin Mutations on HLA Class I Expression in Myeloproliferative Neoplasms.
Effects of Calreticulin Mutations on HLA Class I Expression in Myeloproliferative Neoplasms.
Journal: bioRxiv : the preprint server for biology
Published: July 16, 2025
Similar Doctors
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Dale L. Bixby
Hematology | Oncology | Hematology Oncology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Dale L. Bixby
Hematology | Oncology | Hematology Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Dale Bixby is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Bixby is rated as an Elite provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration. Dr. Bixby is currently accepting new patients.

Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Elias Hazzi
Oncology | Hematology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Elias Hazzi
Oncology | Hematology

W A Foote Memorial Hospital Inc

1100 E Michigan Ave, 307 Henry Ford Allegiance, 
Jackson, MI 
 (33.7 miles away)
517-205-1594
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elias Hazzi is an Oncologist and a Hematologist in Jackson, Michigan. Dr. Hazzi is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Richter Syndrome, and Chronic Lymphocytic Leukemia (CLL). Dr. Hazzi is currently accepting new patients.

Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Mohammed S. Ogaily
Oncology | Hematology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Mohammed S. Ogaily
Oncology | Hematology

Michigan Healthcare Professionals PC

19725 Allen Rd, Suite 101, 
Brownstown Twp, MI 
 (27.4 miles away)
734-479-2371
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Mohammed Ogaily is an Oncologist and a Hematologist in Brownstown Twp, Michigan. Dr. Ogaily is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Angiosarcoma, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast. Dr. Ogaily is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Talpaz's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile